Skip to main content
. 2013 Dec 21;129(3):143–153. doi: 10.1111/ane.12207

Figure 2.

Figure 2

Oxtellar XR (SPN-804) vs placebo: Median percent reduction from baseline 28-day seizure frequency (A) and responder rate (B) for the 16-week double-blind treatment period in ITT population with analyzable data. *= 0.003; **= 0.02 vs placebo. ITT, intent-to-treat.